The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Optimer Pharmaceuticals met expectations on revenues and whiffed on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share expanded.
Margins increased across the board.
Optimer Pharmaceuticals recorded revenue of $64.6 million. The five analysts polled by S&P Capital IQ foresaw a top line of $64.7 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.29. The four earnings estimates compiled by S&P Capital IQ averaged $0.51 per share on the same basis. GAAP EPS were $0.28 for Q4 versus -$0.31 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 93.5%, 763,060 basis points better than the prior-year quarter. Operating margin was 19.7%, 1,120,660 basis points better than the prior-year quarter. Net margin was 20.7%, 766,130 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $19.7 million. On the bottom line, the average EPS estimate is -$0.42.
Next year's average estimate for revenue is $122.3 million. The average EPS estimate is -$1.03.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 104 members out of 135 rating the stock outperform, and 31 members rating it underperform. Among 46 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Optimer Pharmaceuticals a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is buy, with an average price target of $19.70.
Over the decades, small-cap stocks like Optimer Pharmaceuticals have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Optimer Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.